ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two
senior executives to its executive management team. Eric Feldman, M.D.,
a specialist in leukemia and bone marrow disorder therapies, has been
appointed Vice President of Clinical Development. Christian
Dinneen-Long, an attorney with deep experience in the biotechnology
industry, has been appointed Vice President and Corporate Counsel.
“We are pleased to bolster the GlycoMimetics executive team with the
addition of these two very accomplished leaders, and we look forward to
leveraging their expertise as we continue to cultivate our pipeline of
novel, small-molecule glycomimetic therapeutics,” said Chief Executive
Officer Rachel King. “Eric’s extensive background in acute myeloid
leukemia (AML) clinical development and Christian’s strong governance
and transactional experience will both be invaluable to our corporate
advancement, particularly as we move our uproleselan AML program through
late-stage clinical trials.”
Dr. Feldman is internationally recognized for his work in the
development of new therapies for the treatment of leukemias and related
bone marrow disorders. He is the past Editor-in-Chief of the journal Leukemia
Research, Professor of Medicine and Director of the
Hematologic Malignancies Service at Weill Medical College of Cornell
University. In industry, he was Distinguished Clinical Research
Scientist at Seattle Genetics, and he most recently served as Chief
Medical Officer at Amphivena Therapeutics, Inc. Dr. Feldman will report
to GlycoMimetics Senior Vice-President of Clinical Development and Chief
Medical Officer Helen Thackray.
Mr. Dinneen-Long has over 15 years of in-house legal experience at
several public biotech companies, in addition to experience early in his
career at a major Washington, DC law firm. He most recently served as
Senior Counsel at AstraZeneca/MedImmune, where he supported strategic
initiatives, pipeline programs and major business development
transactions. Mr. Dinneen-Long will also serve as GlycoMimetics’
Corporate Secretary and will report to CEO Rachel King.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics’ most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics’ wholly owned drug candidate,
uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is being evaluated
across a range of patient populations including a company-sponsored
Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also
completed a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Contacts
Investor Contact:
Shari Annes
Phone: 650-888-0902
Email:
sannes@annesassociates.com
Media Contact:
Jamie Lacey-Moreira
Phone: 410-299-3310
Email:
jamielacey@presscommpr.com